Study summary
Adding ivonescimab to chemotherapy modestly extended survival after EGFR pills
16.8months median survival, vs 14.1 with chemotherapy alone
What was tested
Ivonescimab, an antibody that blocks both PD-1 and VEGF, or placebo, added to chemotherapy after EGFR pills stopped working. Run in China.
What they found
- Median overall survival was 16.8 vs 14.1 months.
- Severe side effects were more common (67.1% vs 54.7%).
- In the global HARMONi trial, survival was 16.8 vs 14.0 months, which did not reach statistical significance.
What it means
A possible option after resistance; regulators will weigh the global trial.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.